NCT03728673 2026-04-17
A Study Utilizing Escitalopram in Glioma Patients
University of Nebraska
Phase 2 Recruiting
Clinical Trials
39 trialsNCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT05580562 2026-04-16
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT05588141 2026-04-16
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07042620 2026-04-16
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
SonoClear AS
Phase NA Recruiting
NCT06126744 2026-04-15
PuMP
Duke University
Phase 1 Recruiting
NCT06666712 2026-04-15
TPT CED rHGG
Columbia University
Phase 1 Recruiting
NCT05099003 2026-04-14
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT02800486 2026-04-13
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04185038 2026-04-13
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Recruiting
NCT05278208 2026-04-13
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT05859334 2026-04-13
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06344130 2026-04-09
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT05096481 2026-04-08
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06910306 2026-04-06
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT07488754 2026-04-06
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
Medical University of Warsaw
Phase NA Recruiting
NCT05503797 2026-04-03
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
Phase 2 Recruiting
NCT03340506 2026-04-01
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
NCT07374692 2026-04-01
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT05839379 2026-03-31
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
Recruiting
NCT03739411 2026-03-27
Hyperpolarized Imaging in Diagnosing Participants With Glioma
University of California, San Francisco
Phase 1 Recruiting
NCT05355701 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05538130 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT06838676 2026-03-27
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07074756 2026-03-27
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
Mayo Clinic
Phase NA Recruiting
NCT07413796 2026-03-27
NEURO-SUTURE
Medical University of Warsaw
Phase NA Recruiting
NCT06368310 2026-03-25
FIH Clinical Investigation of Graphene Electrodes for Brain Mapping
University of Manchester
Phase NA Recruiting
NCT06482905 2026-03-24
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT05212272 2026-03-23
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Wake Forest University Health Sciences
Phase NA Recruiting
NCT06528691 2026-03-23
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07486713 2026-03-20
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
Phase 4 Recruiting
NCT06161519 2026-03-19
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting